News >

Developments Expanding Frontline NSCLC Treatment

Danielle Bucco
Published: Friday, Apr 13, 2018

Thomas Eldridge Stinchcombe, MD

Thomas Eldridge Stinchcombe, MD
Osimertinib (Tagrisso) and alectinib (Alecensa) are 2 new frontline therapies for patients with non–small cell lung cancer (NSCLC) that have demonstrated tremendous advancements for targeted therapy, said Thomas E. Stinchcombe, MD.

State of the Science Summit™ on Non–Small Cell Lung Cancer, Stinchcombe, a professor in the Division of Medical Oncology at Duke University and member of Duke Cancer Institute, discussed existing and emerging first-line regimens coming through the pipeline for the treatment of patients with NSCLC.

OncLive®: What are your thoughts on osimertinib and alectinib as first-line treatments for patients with NSCLC?

Stinchcombe: There have been tremendous advances with targeted therapy in the last year. A phase III trial compared osimertinib with erlotinib and gefitinib. This revealed an improved PFS with a median of 18.9 months [with osimertinib], which also demonstrated lower grade 3/4 toxicities.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication